Morgan Stanley downgraded Sight Sciences to Equal Weight from Overweight with a price target of $8.40, down from $12. The downgrade is driven partially by the company’s heightened risk profile following Omni reimbursement pressures, the analyst tells investors in a research note. While the firm believes recent proposals will be overturned, it thinks the stock now factors in this expectation, even after falling 30% since late May.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SGHT:
- Sight Sciences price target lowered to $8 from $9 at Citi
- Sight Sciences Reports Second Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
- Sight Sciences backs FY23 revenue view $89M-$94M, consensus $91.67M
- Sight Sciences reports Q2 EPS (30c), consensus (34c)
- Glaukos price target raised to $85 from $80 at Piper Sandler